Aslan Pharmaceuticals Ltd
Change company Symbol lookup
Select an option...
ASLN Aslan Pharmaceuticals Ltd
WYND Wyndham Destinations Inc
GRWWF Great Wall Pan Asia Holdings Ltd
BAC Bank of America Corp
FULC Fulcrum Therapeutics Inc
T AT&T Inc
F Ford Motor Co
JNJ Johnson & Johnson
HHER Her Imports
WSBF Waterstone Financial Inc

Health Care : Biotechnology | Small Cap Value
Based in Singapore
Company profile

ASLAN Pharmaceuticals Limited is a clinical-stage oncology and immunology focused biopharmaceutical company. The Company’s portfolio is comprised of one monoclonal antibody therapy targeting inflammatory disease and two small molecule inhibitors targeting oncology. The Company’s products include ASLAN004, ASLAN003 and Varlitinib. ASLAN004 is a fully human monoclonal antibody that binds to the IL-13 receptor alpha1 subunit (IL-13Rα1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. ASLAN003 is an inhibitor of human dihydroorotate dehydrogenase (DHODH), in acute myeloid leukemia (AML) and are exploring development in other solid tumors. Varlitinib is an oral, reversible small-molecule pan-HER inhibitor.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low

10-day average volume:

electroCore Announces Non-Invasive Vagus Nerve Stimulation Clinical Update Publication in Cephalalgia

8:58 am ET July 28, 2020 (Globe Newswire) Print

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a paper, entitled, "Non-invasive vagus nerve stimulation for primary headache: a clinical update," in Cephalalgia, the official journal of the International Headache Society (IHS).

The paper is a narrative review of recent scientific and clinical research into non-invasive vagus nerve stimulation (nVNS) for headache, including findings from mechanistic studies and their possible relationships to the clinical effects of nVNS. The review concludes that scientific and clinical studies support the emergence of nVNS as an effective, safe, well-tolerated, and practical treatment for primary headache disorders and supports the consideration of nVNS as: (1) a first-line treatment for both the acute and preventive treatment of cluster headache; (2) an effective option for acute treatment of migraine; and (3) a highly relevant, practical option for migraine preventive therapy.

"We are pleased with the scientific review and clinical recommendations made by the authors of this clinical update and hope that these recommendations, which we believe support the use of gammaCore(TM) (nVNS) in the treatment of both cluster and migraine headache, will help drive awareness of this novel technology by physicians and patients alike," said Peter Staats, MD, Chief Medical Officer of electroCore.

Eric Liebler, Senior Vice President, Neurology at electroCore, and a co-author of the paper, commented, "The growing understanding of the first line role of nVNS for the treatment of cluster headache and its ability to be used acutely and preventively in migraine and cluster headache is a credit to the quality of the basic science and clinical trials that support these treatment recommendations."

Dr. Stephen Silberstein, past President the American Headache Society, Director of the Jefferson Headache Center at the Thomas Jefferson University Medical Center, and the first author of the paper, commented, "Over the past several years the basic science and clinical evidence from studies completed across the United States and Europe have shown us not only the clinical benefit of nVNS but how and why it may be working in those patients. The interplay and overlap of the many ways nVNS affects the brain supports its ability to be used as a preventive and acute treatment for both cluster and migraine headache. Neuromodulation is a tool that we feel should be available to our cluster and migraine headache patients who need it."

The paper is available via open access at:

Article funded by electroCore, Inc. See publication for disclosures.

About electroCore, Inc.

electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation (nVNS) therapy initially focused on the treatment of multiple conditions in neurology. The company's current indications are for the preventative treatment of cluster headache and acute treatment of migraine and episodic cluster headache.

For more information, visit

About gammaCore

gammaCore (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient's neck over the vagus nerve, gammaCore stimulates the nerve's afferent fibers, which may lead to a reduction of pain in patients.

gammaCore is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients. gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua), Bronchoconstriction and Medication Overuse Headache in adults. In addition, the FDA has issued an Emergency Use Authorization (EUA) for use of gammaCore Sapphire CV for acute use at home or in a healthcare setting to treat adult patients with known or suspected COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow, and for whom approved drug therapies are not tolerated or provide insufficient symptom relief as assessed by their healthcare provider. The FDA has not cleared gammaCore for the treatment of pneumonia and/or respiratory disorders such as acute respiratory stress disorder associated with COVID-19.

Safety and efficacy of gammaCore have not been evaluated in the following patients:

-- Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)

-- Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)

-- Pediatric patients

-- Pregnant women

-- Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia

Patients should not use gammaCore if they:

-- Have an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device;

-- Have a metallic device such as a stent, bone plate, or bone screw implanted at or near their neck; or

-- Are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone)

Please refer to the gammaCore(TM) and gammaCore Sapphire CV Instructions for Use for all of the important warnings and precautions before using or prescribing this product.

Forward-Looking Statement

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about the potential of nVNS to treat headache, electroCore's business prospects and clinical and product development plans, its pipeline or potential markets for its technologies, the timing, outcome and impact of regulatory, clinical and commercial developments including potential human trials for the study of nVNS in COVID-19 patients in Spain, the U.S., or elsewhere, the business, operating or financial impact of such studies, and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore's business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore(TM), competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at


Hans Vitzthum

LifeSci Advisors



Media Contact:

Jackie Dorsky




Silberstein, S. D., Yuan, H., Najib, U., Ailani, J., Morais, A. L. de, Mathew, P. G., ... Diener, H.-C. (2020). Non-invasive vagus nerve stimulation for primary headache: A clinical update. Cephalalgia.

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.